Glenn F. Pierce, MD, PhD

Glenn F. Pierce, MD, PhD

Glenn Pierce, MD, PhD, currently serves on the World Federation of Hemophilia (WFH) Vice President Medical and WFH USA Board of Directors and National Hemophilia Foundation (NHF) U.S. Medical and Scientific Advisory Council. He is an Entrepreneur in-residence at Third Rock Ventures as well as a consultant for gene therapy and hematology biotech companies. He co-founded Ambys Medicines in 2018, a cell and gene therapy liver regeneration start-up, and serves as the Chief Medical Officer (CMO). Dr. Pierce retired from Biogen in 2014, where he led the R&D of extended half-life FVIII and FIX Fc fusions as CMO. He spearheaded the donation of 1 billion international units (IUs) and initiation of the humanitarian aid collaboration with WFH. Dr. Pierce also led the initiation of the My Life Our Future (MLOF) program to genotype >10,000 individuals in the US bleeding disorder community. Previously, Dr. Pierce served on the NHF Board of Directors and was President of the NHF. Dr. Pierce received an MD and a PhD in Immunology, and did his postgraduate training in pathology and hematology research. He has 30+ years of experience in biotech drug development in the areas of tissue regeneration and hematology, including hemophilia, beginning with Amgen and has been involved in the development of 5 approved products for hemophilia. He splits time between San Francisco and San Diego. Dr. Pierce was born with severe hemophilia A, and was cured in 2008.


Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL